Read More

National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection

The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate the safety and pharmacokinetics of lenacapavir, a bi-annual injectable antiretroviral drug.

GILD

Read More

What’s Going On With CrowdStrike Stock Today?

CrowdStrike Holdings Inc (NASDAQ: CRWD) shares are trading lower Tuesday afternoon ahead of the company's earnings report due after the bell. CrowdStrike is scheduled to report first-quarter earnings results for fiscal 2025 after the market close. Analysts expect EPS of 90 cents and revenue totaling $904.67 million for the quarter, according to Benzinga Pro.

CRWD